What it's for (Indications)
- Trazodone is primarily indicated for the treatment of Major Depressive Disorder (MDD) in adults.
- Its antidepressant effects are thought to be mediated through its complex interaction with serotonergic systems in the central nervous system.
- While not an FDA-approved indication for insomnia, trazodone is widely and commonly prescribed off-label at lower doses for the management of insomnia, particularly in patients for whom sedating side effects are desirable or where other hypnotics are contraindicated or ineffective.
- The therapeutic benefits for MDD typically emerge over several weeks of consistent use, necessitating patient education on adherence and realistic expectations regarding symptom improvement.
- Its use requires careful patient selection and monitoring to ensure efficacy and minimize potential adverse effects, balancing its antidepressant and sedative properties.
- It is important to note that its efficacy in treating depression may be less robust compared to some newer antidepressants, making it often a second-line option for MDD, but a valuable one where sedation is also desired.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | For Major Depressive Disorder, the typical adult starting dose of trazodone hydrochloride is 150 mg/day administered in divided doses. This dosage can be increased by 50 mg/day every 3 to 4 days, as tolerated and clinically indicated, up to a maximum daily dose of 400 mg for outpatients and 600 mg for inpatients, often administered at bedtime or in divided doses to mitigate sedation. Dosing should always be individualized based on the patient’s response, tolerability, and the presence of comorbid conditions. When discontinuing trazodone, a gradual dose reduction is recommended to minimize the risk of withdrawal symptoms, which can include anxiety, agitation, and sleep disturbances, particularly if the drug has been taken for an extended period or at higher doses. For off-label use in insomnia, much lower doses, typically ranging from 25 mg to 100 mg at bedtime, are commonly employed, though these specific dosing guidelines are not FDA-approved and should be determined by a healthcare professional. |
Safety & Warnings
Common Side Effects
- Trazodone is associated with a range of dose-dependent and idiosyncratic side effects, necessitating careful patient counseling and monitoring.
- Common adverse reactions include drowsiness, dizziness, lightheadedness, blurred vision, dry mouth, nausea, vomiting, constipation, and headache.
- Orthostatic hypotension, characterized by a sudden drop in blood pressure upon standing, is a frequent occurrence due to its alpha-adrenergic blocking properties, posing a fall risk, especially in elderly patients or those concomitantly receiving antihypertensive medications.
- Less common but more serious side effects include priapism (prolonged and painful erection), which requires immediate medical attention to prevent permanent penile damage, and cardiac arrhythmias, including QT prolongation and torsades de pointes, though rare, can occur, particularly in patients with pre-existing cardiac conditions or those on concomitant QT-prolonging medications.
- Other potential adverse events include serotonin syndrome (especially with co-administration of other serotonergic drugs), hyponatremia, liver enzyme elevations, and blood dyscrasias.
- Patients should be advised to report any persistent or severe adverse effects to their healthcare provider promptly for appropriate management.
Serious Warnings
- Black Box Warning: **WARNING: SUICIDALITY AND ANTIDEPRESSANT DRUGS** Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of Major Depressive Disorder (MDD) and other psychiatric disorders. Anyone considering the use of trazodone or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults older than 24 years; there was a reduction in risk with antidepressants compared to placebo in adults aged 65 years and older. Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. Trazodone is not approved for use in pediatric patients. This warning underscores the critical importance of vigilant patient monitoring, particularly during the initial phase of treatment or following dose adjustments, to identify and mitigate potential risks and ensure appropriate clinical management in vulnerable populations.
- Patients receiving trazodone should be carefully monitored for the emergence or worsening of depression, suicidal thoughts or behaviors, and unusual changes in behavior, especially during the initial stages of treatment or following dose adjustments.
- While not a formal black box warning for adults over 24, this vigilance is crucial across all age groups.
- Trazodone can induce orthostatic hypotension and syncope, particularly during the initial titration phase and with concomitant use of antihypertensive agents or alcohol; patients should be cautioned about these risks and advised to rise slowly from a sitting or lying position.
- Cases of priapism have been reported, requiring immediate medical intervention as prolonged erection can lead to permanent damage.
- Cardiac arrhythmias, including ventricular premature beats, couplets, and even more serious arrhythmias such as ventricular tachycardia, have occurred; caution is advised in patients with pre-existing cardiac disease.
- Serotonin Syndrome can occur when trazodone is co-administered with other serotonergic agents.
- Angle-closure glaucoma risk can also be increased due to pupillary dilation, requiring careful assessment in susceptible patients.
- Impairment of cognitive and motor functions may occur, thus patients should be advised against operating hazardous machinery or driving until they know how trazodone affects them.
- Dosage adjustments may be necessary in patients with hepatic or renal impairment due to altered drug metabolism and excretion.
How it Works (Mechanism of Action)
Trazodone hydrochloride is classified pharmacologically as a serotonin antagonist and reuptake inhibitor (SARI), belonging to the phenylpiperazine class. Its primary antidepressant and anxiolytic effects are believed to be mediated through its complex interaction with various neurotransmitter systems. Trazodone acts as a potent antagonist of serotonin 5-HT2A and 5-HT2C receptors, which is thought to contribute to its antidepressant properties and may mitigate some of the activating side effects associated with selective serotonin reuptake inhibitors (SSRIs) by blocking certain serotonin receptors that can cause anxiety or insomnia. Concurrently, it weakly inhibits serotonin reuptake, contributing to an increased extracellular serotonin concentration, albeit less potently than SSRIs. Additionally, trazodone exhibits antagonism at alpha-1 adrenergic receptors, which is responsible for its common side effects of orthostatic hypotension and sedation. It also possesses moderate antihistaminic (H1) properties, further contributing to its sedative effects, making it effective for treating insomnia. These multifaceted pharmacological actions distinguish trazodone from other classes of antidepressants, providing both antidepressant and significant sedative benefits, particularly at different dose ranges.
Commercial Brands (Alternatives)
No other brands found for this formula.